Streetbeat News

Price Targets

AVO

Stephens & Co. has maintained its Overweight rating on Mission Produce (NASDAQ:AVO) but reduced its price target from $13.00 to $12.00. Mission Produce's shares have fallen 5.43% to $9.05. The new target implies a 32.6% upside. Mission Produce operates in avocado production and distribution, with additional services like ripening and logistical management. The company earns most revenue from its Marketing and Distribution segment.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:00 pm

BBWI

Wells Fargo has maintained its Equal-Weight rating on Bath & Body Works (NYSE:BBWI) and increased its price target from $35.00 to $40.00. Despite this, BBWI shares are currently trading down at $43.40, which is above the new target price. Bath & Body Works operates primarily in North America with a focus on home fragrance and body care retail, expecting growth through store reformatting and digital expansion.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:00 pm

AIR

Stifel has reaffirmed its Buy rating on AAR Corp (NYSE:AIR) and increased its price target from $80.00 to $81.00. Despite the upgrade, AAR's stock is currently down 5.35% at $67.00 per share. An increase to the new price target would represent a 20.9% upside. AAR provides products and services to the aviation, government, and defense sectors, with the majority of its revenue coming from the Aviation Services segment.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:00 pm

ISRG

Truist Securities has reaffirmed its Buy rating on Intuitive Surgical (NASDAQ:ISRG) and increased its price target from $375.00 to $390.00. Despite a slight decline in share price over the last 24 hours, the new price target suggests a potential upside of 17.57% from the current price of $331.72. Intuitive Surgical is known for its da Vinci robotic surgical systems, with over 8,000 units installed globally.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:00 pm

KRTX

Wedbush analyst Laura Chico downgraded Karuna Therapeutics (NASDAQ:KRTX) from Outperform to Neutral, while setting a price target of $330.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 4:58 pm

KRTX

Morgan Stanley analyst Jeffrey Hung has downgraded Karuna Therapeutics (NASDAQ:KRTX) from Overweight to Equal-Weight, while also raising the price target from $295 to $330.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 4:53 pm

ALVR

Leerink Partners analyst Mani Foroohar downgraded AlloVir (NASDAQ:ALVR) from Outperform to Market Perform and set a price target of $1. This represents a significant change in the firm's outlook on AlloVir's stock performance.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 4:50 pm

RKLB

Cantor Fitzgerald analyst Andres Sheppard has reiterated an Overweight rating on Rocket Lab USA (NASDAQ:RKLB) and maintained a price target of $6. This reaffirmation of the company's stock rating and price target suggests continued confidence in Rocket Lab's prospects.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 4:39 pm

HBM

BMO Capital analyst Jackie Przybylowski has reinstated Hudbay Minerals (TSX:HBM) with an Outperform rating but has lowered the price target from C$9.5 to C$8.5.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 4:27 pm

KURA

Kura Oncology's stock is experiencing an uptick following Mizuho's initiation of coverage with a Buy rating and a price target of $26.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 4:10 pm